Abstract: A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration.
Abstract: Provided is a microsphere comprising a bead coated with a first calcium-containing mineral. Also provided is a method of producing a microsphere. Additionally, a method of administering a compound to a vertebrate is provided.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
March 21, 2023
Assignee:
TRS HOLDINGS LLC
Inventors:
William L. Murphy, Leenaporn Jongpaiboonkit
Abstract: The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
February 14, 2023
Assignees:
Elanco US Inc., Ambrx, Inc.
Inventors:
Peter Connor Canning, Nickolas Knudsen, Md Harunur Rashid
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
Type:
Grant
Filed:
November 11, 2015
Date of Patent:
January 31, 2023
Assignee:
Cytiva BioProcess R&D AB
Inventors:
Gustav Rodrigo, Tomas Bjorkman, Mats Ander
Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumour or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.
Type:
Grant
Filed:
December 9, 2020
Date of Patent:
January 10, 2023
Assignee:
Peptide Patents AS
Inventors:
Wenche Stensen, Frederick A. Leeson, Oystein Rekdal, John S. Svendsen
Abstract: [Problems] To provide a method for treating and/or preventing osteoporosis with teriparatide or a salt thereof, the method having excellent safety and/or efficacies. [Solving Means] A method for treating and/or preventing osteoporosis in which teriparatide or a salt thereof is an active ingredient, including administering teriparatide or a salt thereof in a unit dose of 28.2 ?g at a frequency of twice a week.
Abstract: The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, hyperlipidemia, inflammatory diseases or inflammatory response to infection.
Abstract: The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.
Type:
Grant
Filed:
November 10, 2020
Date of Patent:
June 28, 2022
Assignee:
Morehouse School of Medicine
Inventors:
Gale W. Newman, James W. Lillard, Jr., Chamberlain Obialo
Abstract: The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.
Abstract: C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.
Abstract: The antitumor peptide provided by the present invention is a synthetic peptide including both of: (1) an amino acid sequence composing the second transmembrane region from the N-terminal of a membrane protein sphingosine 1-phosphate receptor 1 (S1PR1), or a modified amino acid sequence formed by deletion substitution or addition of 1, 2 or 3 amino acid residues in the amino acid sequence; and (2) an amino acid sequence functioning as a cell-penetrating peptide (CPP); wherein the total number of amino acid residues is 100 or less.
Type:
Grant
Filed:
July 30, 2019
Date of Patent:
May 24, 2022
Assignees:
Toagosei Co., Ltd., National University Corporation Nagoya University
Abstract: Methods for treating obesity are provided and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods for reducing adiposity and adipogenesis are also provided and make use of a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject.
Type:
Grant
Filed:
January 29, 2016
Date of Patent:
April 26, 2022
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Inventors:
Zijian Xie, Joseph I. Shapiro, Nader G. Abraham, Komal Sodhi
Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
Type:
Grant
Filed:
July 29, 2020
Date of Patent:
April 26, 2022
Assignee:
BicycleTx Limited
Inventors:
Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
April 19, 2022
Assignee:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Vincent C. Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin N. Shelton
Abstract: According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
March 22, 2022
Assignee:
ARECOR LIMITED
Inventors:
David Gerring, Leon Zakrzewski, Jan Jezek, Sarah Howell
Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
March 15, 2022
Assignee:
Second Genome, Inc.
Inventors:
Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
Abstract: Disclosed are oxytocin compositions having a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist for the treatment of neonatal abstinence syndrome (“NAS”) in a subject. Also disclosed are methods for the treatment of NAS by administering a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist to a subject.
Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.
Type:
Grant
Filed:
January 30, 2018
Date of Patent:
February 22, 2022
Assignees:
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.
Inventors:
Tetsuji Yamaoka, Maria Chiara Munisso, Atsushi Mahara, Takashi Yamamoto
Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.